Publications by authors named "Honami Ishikawa"

Programmed death ligand-1 (PD-L1) is one of the immune checkpoint molecule localized on the plasma membrane of numerous cancer cells that negatively regulates T-cell-mediated immunosurveillance. Despite the remarkable efficacy and safety profile of immune checkpoint inhibitors (ICIs), such as anti-PD-L1 antibodies, restricted poor therapeutic responses to ICIs are often observed in patients with ovarian cancer. Because higher expression of PD-L1 in advanced ovarian cancer is associated with a decreased survival rate, identifying the potential molecules to regulate the plasma membrane expression of PD-L1 may provide a novel therapeutic strategy to improve the efficacy of ICIs against ovarian cancers.

View Article and Find Full Text PDF